Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2022

Aug 04, 2022

SELL
$7.06 - $25.52 $706 - $2,552
-100 Closed
0 $0
Q1 2022

Apr 14, 2022

SELL
$23.34 - $36.08 $35,010 - $54,120
-1,500 Reduced 93.75%
100 $0
Q4 2021

Jan 18, 2022

BUY
$17.63 - $37.1 $19,393 - $40,810
1,100 Added 220.0%
1,600 $8,000
Q3 2021

Oct 26, 2021

BUY
$12.95 - $49.69 $6,475 - $24,845
500 New
500 $0

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.04B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.